Search - tctmd.com

Displaying 1 - 20 of 78

Sort: Relevancy | Date

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

L.A. McKeown

August 12, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

Presentation TCT 2024

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

Presenter: Pier Pasquale Leone

October 30, 2024

Presentation TCT 2024

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

Presenter: Ikuta Akihiro

October 29, 2024

Presentation TCT 2024

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Presenter: Dealla Samadi

October 29, 2024

Presentation TCT 2024

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

Presenter: Ulf Teichgräber

October 29, 2024

Presentation TCT 2024

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Jennifer Tremmel

October 29, 2024

Presentation TCT 2024

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

Presenter: Akihiro Tobe

October 29, 2024

Presentation TCT 2024

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

Presenter: Shelby Kerr

October 29, 2024

Presentation TCT 2024

TCT 41: Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis

Presenter: Doosup Shin

October 28, 2024

Presentation TCT 2024

TCT 40: Sirolimus- vs. Paclitaxel-Coated Balloons for Treatment of Coronary Artery Disease

Presenter: Pier Pasquale Leone

October 28, 2024

Presentation TCT 2024

TCT 491: AGENT Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in Small Vessel Coronary Lesions: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Suhail Dohad

October 28, 2024

Presentation TCT 2024

TCT 436: Paclitaxel-Coated Balloon With Urea or Iopromide as the Excepient for Treatment of Coronary Artery Disease: A Propensity-Score Adjusted Comparison

Presenter: Mauro Gitto

October 28, 2024

Presentation TCT 2024

TCT 492: One-Year Clinical Outcomes After PCI With AGENT Paclitaxel-Coated Balloon Among Underrepresented Racial and Ethnic Subgroups With In-Stent Restenosis: Analysis of the AGENT IDE Trial

Presenter: NULL

October 28, 2024

Presentation TCT 2024

TCT 446: Long-term Outcomes and Impact of Diabetes Mellitus in Patients Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

Presenter: Gakuto Bando

October 28, 2024

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

Todd Neale

September 09, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Advertisement

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Top Coronary Artery Disease News in 2024

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

TCT 41: Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis

TCT 40: Sirolimus- vs. Paclitaxel-Coated Balloons for Treatment of Coronary Artery Disease

TCT 491: AGENT Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in Small Vessel Coronary Lesions: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 436: Paclitaxel-Coated Balloon With Urea or Iopromide as the Excepient for Treatment of Coronary Artery Disease: A Propensity-Score Adjusted Comparison

TCT 492: One-Year Clinical Outcomes After PCI With AGENT Paclitaxel-Coated Balloon Among Underrepresented Racial and Ethnic Subgroups With In-Stent Restenosis: Analysis of the AGENT IDE Trial

TCT 446: Long-term Outcomes and Impact of Diabetes Mellitus in Patients Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content